Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Matías A. Ávila:

Amphiregulin. Berasain C et al. Semin Cell Dev Biol. (2014)

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gerbes A et al. Gut. (2018)

Emerging therapies for acute intermittent porphyria. Fontanellas A et al. Expert Rev Mol Med. (2016)

Search results

Items: 1 to 20 of 99

1.

Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis.

Argemi J, Latasa MU, Atkinson SR, Blokhin IO, Massey V, Gue JP, Cabezas J, Lozano JJ, Van Booven D, Bell A, Cao S, Vernetti LA, Arab JP, Ventura-Cots M, Edmunds LR, Fondevilla C, Stärkel P, Dubuquoy L, Louvet A, Odena G, Gomez JL, Aragon T, Altamirano J, Caballeria J, Jurczak MJ, Taylor DL, Berasain C, Wahlestedt C, Monga SP, Morgan MY, Sancho-Bru P, Mathurin P, Furuya S, Lackner C, Rusyn I, Shah VH, Thursz MR, Mann J, Avila MA, Bataller R.

Nat Commun. 2019 Jul 16;10(1):3126. doi: 10.1038/s41467-019-11004-3.

2.

Current and innovative emerging therapies for porphyrias with hepatic involvement.

Fontanellas A, Ávila MA, Anderson KE, Deybach JC.

J Hepatol. 2019 Aug;71(2):422-433. doi: 10.1016/j.jhep.2019.05.003. Epub 2019 May 16. Review.

PMID:
31102718
3.

Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.

Lozano E, Macias RIR, Monte MJ, Asensio M, Del Carmen S, Sanchez-Vicente L, Alonso-Peña M, Al-Abdulla R, Munoz-Garrido P, Satriano L, O'Rourke CJ, Banales JM, Avila MA, Martinez-Chantar ML, Andersen JB, Briz O, Marin JJG.

Hepatology. 2019 Apr 10. doi: 10.1002/hep.30656. [Epub ahead of print]

PMID:
30972782
4.

Chromatin dynamics during liver regeneration.

Arechederra M, Berasain C, Avila MA, Fernández-Barrena MG.

Semin Cell Dev Biol. 2019 Apr 9. pii: S1084-9521(18)30193-9. doi: 10.1016/j.semcdb.2019.03.004. [Epub ahead of print] Review.

PMID:
30940574
5.

Messenger RNA therapy for rare genetic metabolic diseases.

Berraondo P, Martini PGV, Avila MA, Fontanellas A.

Gut. 2019 Jul;68(7):1323-1330. doi: 10.1136/gutjnl-2019-318269. Epub 2019 Feb 22. Review.

PMID:
30796097
6.

Role of AGAP2 in the profibrogenic effects induced by TGFβ in LX-2 hepatic stellate cells.

Navarro-Corcuera A, López-Zabalza MJ, Martínez-Irujo JJ, Álvarez-Sola G, Ávila MA, Iraburu MJ, Ansorena E, Montiel-Duarte C.

Biochim Biophys Acta Mol Cell Res. 2019 Apr;1866(4):673-685. doi: 10.1016/j.bbamcr.2019.01.008. Epub 2019 Jan 17.

PMID:
30660615
7.

Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins.

Jiménez M, Urtasun R, Elizalde M, Azkona M, Latasa MU, Uriarte I, Arechederra M, Alignani D, Bárcena-Varela M, Álvarez-Sola G, Colyn L, Santamaría E, Sangro B, Rodriguez-Ortigosa C, Fernández-Barrena MG, Ávila MA, Berasain C.

Nucleic Acids Res. 2019 Apr 23;47(7):3450-3466. doi: 10.1093/nar/gkz014.

8.

Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.

Al-Abdulla R, Lozano E, Macias RIR, Monte MJ, Briz O, O'Rourke CJ, Serrano MA, Banales JM, Avila MA, Martinez-Chantar ML, Geier A, Andersen JB, Marin JJG.

Br J Pharmacol. 2019 Mar;176(6):787-800. doi: 10.1111/bph.14563. Epub 2019 Feb 11.

PMID:
30592786
9.

Targeting CCL2/CCR2 in Tumor-Infiltrating Macrophages: A Tool Emerging Out of the Box Against Hepatocellular Carcinoma.

Avila MA, Berasain C.

Cell Mol Gastroenterol Hepatol. 2019;7(2):293-294. doi: 10.1016/j.jcmgh.2018.11.002. Epub 2018 Dec 4. No abstract available.

10.

Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability.

Jimenez M, Arechederra M, Ávila MA, Berasain C.

Transl Gastroenterol Hepatol. 2018 Oct 31;3:84. doi: 10.21037/tgh.2018.10.11. eCollection 2018. Review.

11.

The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis.

Santamaría E, Rodríguez-Ortigosa CM, Uriarte I, Latasa MU, Urtasun R, Alvarez-Sola G, Bárcena-Varela M, Colyn L, Arcelus S, Jiménez M, Deutschmann K, Peleteiro-Vigil A, Gómez-Cambronero J, Milkiewicz M, Milkiewicz P, Sangro B, Keitel V, Monte MJ, Marin JJG, Fernández-Barrena MG, Ávila MA, Berasain C.

Hepatology. 2019 Apr;69(4):1632-1647. doi: 10.1002/hep.30348. Epub 2019 Mar 4.

PMID:
30411380
12.

Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.

Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntané J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR.

Hepatology. 2019 Aug;70(2):547-562. doi: 10.1002/hep.30319. Epub 2019 Feb 14.

PMID:
30325540
13.

Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.

Jiang L, Berraondo P, Jericó D, Guey LT, Sampedro A, Frassetto A, Benenato KE, Burke K, Santamaría E, Alegre M, Pejenaute Á, Kalariya M, Butcher W, Park JS, Zhu X, Sabnis S, Kumarasinghe ES, Salerno T, Kenney M, Lukacs CM, Ávila MA, Martini PGV, Fontanellas A.

Nat Med. 2018 Dec;24(12):1899-1909. doi: 10.1038/s41591-018-0199-z. Epub 2018 Oct 8.

PMID:
30297912
14.

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis.

Fernández-Ramos D, Fernández-Tussy P, Lopitz-Otsoa F, Gutiérrez-de-Juan V, Navasa N, Barbier-Torres L, Zubiete-Franco I, Simón J, Fernández AF, Arbelaiz A, Aransay AM, Lavín JL, Beraza N, Perugorria MJ, Banales JM, Villa E, Fraga MF, Anguita J, Avila MA, Berasain C, Iruzibieta P, Crespo J, Lu SC, Varela-Rey M, Mato JM, Delgado TC, Martínez-Chantar ML.

Cell Death Dis. 2018 Sep 20;9(10):958. doi: 10.1038/s41419-018-1014-y.

15.

Fibroblast growth factors 19 and 21 in acute liver damage.

Shan Z, Alvarez-Sola G, Uriarte I, Arechederra M, Fernández-Barrena MG, Berasain C, Ju C, Avila MA.

Ann Transl Med. 2018 Jun;6(12):257. doi: 10.21037/atm.2018.05.26. Review.

16.

Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.

Bárcena-Varela M, Caruso S, Llerena S, Álvarez-Sola G, Uriarte I, Latasa MU, Urtasun R, Rebouissou S, Alvarez L, Jimenez M, Santamaría E, Rodriguez-Ortigosa C, Mazza G, Rombouts K, San José-Eneriz E, Rabal O, Agirre X, Iraburu M, Santos-Laso A, Banales JM, Zucman-Rossi J, Prósper F, Oyarzabal J, Berasain C, Ávila MA, Fernández-Barrena MG.

Hepatology. 2019 Feb;69(2):587-603. doi: 10.1002/hep.30168. Epub 2019 Jan 4.

PMID:
30014490
17.

Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk.

Al-Aqil FA, Monte MJ, Peleteiro-Vigil A, Briz O, Rosales R, González R, Aranda CJ, Ocón B, Uriarte I, de Medina FS, Martinez-Augustín O, Avila MA, Marín JJG, Romero MR.

Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):2927-2937. doi: 10.1016/j.bbadis.2018.06.003. Epub 2018 Jun 6.

PMID:
29883717
18.

LKB1: Controlling Quiescence and Genomic Integrity at Home.

Berasain C, Ávila MA.

Trends Endocrinol Metab. 2018 Oct;29(10):668-670. doi: 10.1016/j.tem.2018.03.017. Epub 2018 Apr 5.

PMID:
29628399
19.

Inhibiting Cytokinesis in the Liver: A New Way to Reduce Tumor Development.

Desdouets C, Avila MA.

Gastroenterology. 2018 Apr;154(5):1229-1231. doi: 10.1053/j.gastro.2018.03.006. Epub 2018 Mar 3. No abstract available.

PMID:
29510129
20.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

Supplemental Content

Loading ...
Support Center